Literature DB >> 33586770

Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy.

Yuqi Zhou1, Colby R Maldini1, Julie Jadlowsky1, James L Riley1.   

Abstract

HIV-infected individuals successfully controlling viral replication via antiretroviral therapy often have a compromised HIV-specific T-cell immune response due to the lack of CD4 T-cell help, viral escape, T-cell exhaustion, and reduction in numbers due to the withdrawal of cognate antigen. A successful HIV cure strategy will likely involve a durable and potent police force that can effectively recognize and eliminate remaining virus that may emerge decades after an individual undergoes an HIV cure regimen. T cells are ideally suited to serve in this role, but given the state of the HIV-specific T-cell response, it is unclear how to best restore HIV-specific T-cell activity prior initiation of a HIV cure strategy. Here, we review several strategies of generating HIV-specific T cells ex vivo that are currently being tested in the clinic and discuss how infused T cells can be part of an HIV cure strategy.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  T-cell exhaustion; T-cell receptor; antiretroviral therapy; chimeric antigen receptor; ex vivo T-cell expansion; human-immunodeficiency-virus; latency reversing agent

Mesh:

Year:  2021        PMID: 33586770      PMCID: PMC7883023          DOI: 10.1093/infdis/jiaa223

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  62 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Authors:  Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

4.  HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.

Authors:  Rebecca M Lynch; Patrick Wong; Lillian Tran; Sijy O'Dell; Martha C Nason; Yuxing Li; Xueling Wu; John R Mascola
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

5.  Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template.

Authors:  Blythe D Sather; Guillermo S Romano Ibarra; Karen Sommer; Gabrielle Curinga; Malika Hale; Iram F Khan; Swati Singh; Yumei Song; Kamila Gwiazda; Jaya Sahni; Jordan Jarjour; Alexander Astrakhan; Thor A Wagner; Andrew M Scharenberg; David J Rawlings
Journal:  Sci Transl Med       Date:  2015-09-30       Impact factor: 17.956

6.  Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.

Authors:  Aviva Joseph; Jian Hua Zheng; Antonia Follenzi; Teresa Dilorenzo; Kaori Sango; Jaime Hyman; Ken Chen; Alicja Piechocka-Trocha; Christian Brander; Erik Hooijberg; Dario A Vignali; Bruce D Walker; Harris Goldstein
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

7.  HIV-1 Vpu Mediates HLA-C Downregulation.

Authors:  Richard Apps; Gregory Q Del Prete; Pramita Chatterjee; Abigail Lara; Zabrina L Brumme; Mark A Brockman; Stuart Neil; Suzanne Pickering; Douglas K Schneider; Alicja Piechocka-Trocha; Bruce D Walker; Rasmi Thomas; George M Shaw; Beatrice H Hahn; Brandon F Keele; Jeffrey D Lifson; Mary Carrington
Journal:  Cell Host Microbe       Date:  2016-05-11       Impact factor: 21.023

8.  Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Authors:  Ariel Halper-Stromberg; Ching-Lan Lu; Florian Klein; Joshua A Horwitz; Stylianos Bournazos; Lilian Nogueira; Thomas R Eisenreich; Cassie Liu; Anna Gazumyan; Uwe Schaefer; Rebecca C Furze; Michael S Seaman; Rab Prinjha; Alexander Tarakhovsky; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Cell       Date:  2014-08-14       Impact factor: 41.582

9.  Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys.

Authors:  Erica N Borducchi; Crystal Cabral; Kathryn E Stephenson; Jinyan Liu; Peter Abbink; David Ng'ang'a; Joseph P Nkolola; Amanda L Brinkman; Lauren Peter; Benjamin C Lee; Jessica Jimenez; David Jetton; Jade Mondesir; Shanell Mojta; Abishek Chandrashekar; Katherine Molloy; Galit Alter; Jeffrey M Gerold; Alison L Hill; Mark G Lewis; Maria G Pau; Hanneke Schuitemaker; Joseph Hesselgesser; Romas Geleziunas; Jerome H Kim; Merlin L Robb; Nelson L Michael; Dan H Barouch
Journal:  Nature       Date:  2016-11-09       Impact factor: 49.962

10.  Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P Moss; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; A Hurley; M Markowitz; D D Ho; A J McMichael; D F Nixon
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more
  3 in total

1.  Allogeneic MHC-matched T-cell receptor α/β-depleted bone marrow transplants in SHIV-infected, ART-suppressed Mauritian cynomolgus macaques.

Authors:  Jason T Weinfurter; Saritha S D'Souza; Lea M Matschke; Sarah Bennett; Laurel E Kelnhofer-Millevolte; Kran Suknuntha; Akhilesh Kumar; Jennifer Coonen; Christian M Capitini; Peiman Hematti; Thaddeus G Golos; Igor I Slukvin; Matthew R Reynolds
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

2.  CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.

Authors:  Pablo Tebas; Julie K Jadlowsky; Pamela A Shaw; Lifeng Tian; Erin Esparza; Andrea L Brennan; Sukyung Kim; Soe Yu Naing; Max W Richardson; Ashley N Vogel; Colby R Maldini; Hong Kong; Xiaojun Liu; Simon F Lacey; Anya M Bauer; Felicity Mampe; Lee P Richman; Gary Lee; Dale Ando; Bruce L Levine; David L Porter; Yangbing Zhao; Don L Siegel; Katharine J Bar; Carl H June; James L Riley
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 19.456

3.  Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque.

Authors:  Gavin I Ellis; Kimberly E Coker; Delaine W Winn; Mosha Z Deng; Divanshu Shukla; Vijay Bhoj; Michael C Milone; Wei Wang; Chengyang Liu; Ali Naji; Raimon Duran-Struuck; James L Riley
Journal:  Cell Rep Med       Date:  2022-05-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.